Lacosamide , 98% , 175481-36-4
CAS NO.:175481-36-4
Empirical Formula: C13H18N2O3
Molecular Weight: 250.29
MDL number: MFCD08272557
EINECS: 605-756-0
Pack Size | Price | Stock | Quantity |
10MG | RMB388.00 | In Stock |
|
1g | RMB508.80 | In Stock |
|
25MG | RMB1008.00 | In Stock |
|
50MG | RMB1094.40 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 141-143?C |
alpha | D23 +16.0° (c = 1 in CH3OH) |
Boiling point: | 536.4±50.0 °C(Predicted) |
Density | 1.120±0.06 g/cm3(Predicted) |
Flash point: | 2℃ |
storage temp. | Refrigerator |
solubility | DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml |
form | A crystalline solid |
pka | 14.19±0.46(Predicted) |
color | white to beige |
optical activity | [α]/D 13 to 18° (C=0.5g/100mL, MeOH) |
InChI | InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1 |
InChIKey | VPPJLAIAVCUEMN-GFCCVEGCSA-N |
SMILES | C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC |
CAS DataBase Reference | 175481-36-4 |
Description and Uses
Although epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.
A potent anticonvulsant.
Safety
Symbol(GHS) | ![]() ![]() GHS02,GHS07 |
Signal word | Danger |
Hazard statements | H225-H302+H312+H332-H319 |
Precautionary statements | P210-P280-P305+P351+P338 |
Hazard Codes | F,Xn |
Risk Statements | 11-20/21/22-36 |
Safety Statements | 16-26-36/37 |
RIDADR | UN 1648 3 / PGII |
WGK Germany | 2 |
HS Code | 2924296000 |